Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Invested Capital (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Invested Capital for 16 consecutive years, with $487.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 34.13% to $487.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $487.9 million, a 34.13% decrease, with the full-year FY2025 number at $487.9 million, down 34.13% from a year prior.
  • Invested Capital was $487.9 million for Q4 2025 at Myriad Genetics, down from $492.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.0 billion in Q1 2021 to a low of $447.5 million in Q2 2025.
  • A 5-year average of $805.6 million and a median of $810.8 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: increased 6.68% in 2024, then crashed 42.66% in 2025.
  • Myriad Genetics' Invested Capital stood at $967.8 million in 2021, then fell by 8.47% to $885.8 million in 2022, then dropped by 7.24% to $821.7 million in 2023, then dropped by 9.86% to $740.7 million in 2024, then plummeted by 34.13% to $487.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Invested Capital are $487.9 million (Q4 2025), $492.3 million (Q3 2025), and $447.5 million (Q2 2025).